Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.62 |
| ▸ | FAAH | O00519 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 10/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30349 | 1.00 | SLC6A5 (0.62) | SLC6A5FAAHMEN1TP53CYP1A2 | |
| SCHEMBL25711820 | 1.00 | SLC6A5 (0.62) | SLC6A5FAAHMEN1TP53CYP1A2 | |
| SCHEMBL9800921 | 1.00 | SLC6A5 (0.62) | SLC6A5FAAHMEN1TP53CYP1A2 | |
| SCHEMBL769868 | 1.00 | SLC6A5 (0.62) | SLC6A5FAAHMEN1TP53CYP1A2 | |
| SCHEMBL769870 | 1.00 | SLC6A5 (0.62) | SLC6A5FAAHMEN1TP53CYP1A2 | |
| SCHEMBL3096362 | 1.00 | SLC6A5 (0.62) | SLC6A5FAAHMEN1TP53CYP1A2 | |
| SCHEMBL6332840 | 0.95 | KDM4E (0.65) | SOAT1KDM4E | |
| SCHEMBL5146257 | 0.95 | KDM4E (0.65) | SOAT1KDM4E | |
| SCHEMBL29619662 | 0.95 | KDM4E (0.65) | SOAT1KDM4E | |
| SCHEMBL1702127 | 0.91 | EPHX2 (0.60) | SLC6A5EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250019341-A1 | COMPOUNDS AND METHOD OF USE THEREOF FOR TREATING BACTERIAL DISEASES | INSTITUTE OF GENETICS AND DEVELOPMENTAL BIOLOGY, CHINESE ACADEMY OF SCIENCES (CN) | 2025-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250019341-A1 | COMPOUNDS AND METHOD OF USE THEREOF FOR TREATING BACTERIAL DISEASES | TLR3, CGAS, NOD2 | SLC6A5 577/4885FAAH 4292/4885MEN1 4010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.